Seasoned team to drive forward pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT)Follows recent appointments of Professor Ton Logtenberg as non-executive Chairman and Ray Barlow as Chief Executive Officer Dublin, Ireland, August 3, 2021: SynOx Therapeutics Limi... read more

HAMILTON, ON and BOSTON, July 28, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the U.S. Food and Drug Administration... read more

July 28, 2021Regulatory STOCKHOLM — July 28, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration, FDA, has issued a saf... read more

Newly Published Data Shows Positive, Durable Benefits of the Only Minimally Invasive Treatment Approved for Patients with Homogeneous Emphysema, a Form of Severe COPD with Widespread Destruction of Lung Tissue REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 27, 2021-- Pulmonx Corporat... read more

Plans to initiate a pivotal trial for patients suffering from Tenosynovial Giant Cell Tumours (TGCT)Follows €37 M Series A investment to progress emactuzumab, a potentially best-in-class CSF-1R antibody licensed on an exclusive, worldwide basis from Roche Dublin, Ireland, July 27, 2021:&n... read more